Investing in Bold Ideas


At Evotec we are investing in bold ideas together with our partners. Through access to our cutting-edge highly innovative platforms, technologies, and our outstanding drug discovery expertise, we enable our Newcos to realize their bold ideas with the goal of developing medicines that matter to transform the lives of patients.

Our Approach

Since 2016 Evotec Ventures has invested over € 150 m in breakthrough innovation. We are pushing the boundaries of drug discovery and development to create breakthrough medicines.

We focus our investments on building early-stage pioneering biotechnology companies. Evotec Ventures provides not only seed stage funding, but also operational and strategic support empowering companies to accelerate their innovation potential.

We build longstanding relationships with our venture partners and leading entrepreneurs to create paradigm changing biotechnology companies.

Meet Our Partners

We invest in areas of high unmet medical need including oncology, metabolic diseases, neuroscience and public health. Our portfolio consists of 23 active investments.

Evotec, our primary drug discovery partner, also an investor, ensures strong alignment of interests as we work to develop targeted therapies modulating DDR pathways in cancer cells.
Daniel Speidel - Breakpoint Therapeutics
Evotec has been an instrumental pillar for Topas, from inception to building all the way a foundational partnership with trust and a true value creation mindset.
Erich Greiner - Topas Therapeutics

You might be interested in...


Alliance Management

Meet our team.

Learn more
Sabine Den Hartogh

Sabine Den Hartogh, PhD

VP Investment Principal Equity

Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.